Subcommittee的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列問答集和懶人包總整理

Mayo Clinic on Crohn’’s Disease and Ulcerative Colitis: Strategies to Manage Your Ibd and Thrive

為了解決Subcommittee的問題，作者Farraye, Francis A.,Kane, Sunanda V. 這樣論述：

Francis A. Farraye, MD, MS, is the director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida, and a professor of medicine at the Mayo Clinic School of Medicine. A gastroenterologist and clinical investigator who has been practicing for 33 years, he runs an academi

c practice managing patients with IBD. A frequent speaker on the diagnosis and management of the disease, he has authored or coauthored more than 450 scientific manuscripts, chapters, reviews, and abstracts. He is editor in chief of the Inflammatory Bowel Disease Journal Scan published weekly by the

American Society of Gastrointestinal Endoscopy. He coedited Curbside Consultation in Inflammatory Bowel Disease and GI Emergencies. The New England Crohn’s and Colitis Foundation named him their humanitarian of the year (2003) and gave him their lifetime achievement award (2020). In 2009, he receiv

ed the William Carey Award from the American College of Gastroenterology for service to the college. A fellow of the American Society of Gastrointestinal Endoscopy and the American Gastroenterological Association and a master in the American College of Gastroenterology, Dr. Farraye lives in Jacksonv

ille, Florida. Sunanda V. Kane, MD, MSPH, is a professor of medicine at the Mayo Clinic in Rochester, Minnesota; physician chair of the Mayo Clinic Quality Academy’s Fellow Subcommittee; and assistant chair of patient experience in the Gastroenterology and Hepatology Division of the Mayo Clinic. Dr.

Kane, who has been practicing medicine for 22 years, served as president of the American College of Gastroenterology from 2018 to 2019 and recently completed a five-year term on the Gastroenterology Specialty Council of the American Board of Internal Medicine. She also chaired the National Patient

Education Committee for the Crohn’s and Colitis Foundation. She runs a clinical practice that reflects her expertise in IBD, and her research focuses on new therapies, gender-specific issues, and medication adherence. In addition to the first two editions of this book, she has written more than 200

chapters, articles, and reviews. She was the first woman associate editor of Alimentary Pharmacology & Therapeutics, is IBD section editor for UpToDate, and serves in various editorial roles for other journals. Dr. Kane lives in Rochester, Minnesota.

Subcommittee進入發燒排行的影片

客家博物館數位典藏詮釋資料欄位探討：以客家文化資產數位網為例

為了解決Subcommittee的問題，作者吳詩婷 這樣論述：

博物館肩負著保存、傳承人類歷史文明、文化知識的重責大任，隨著網際網路的發展，文物數位化成了文化資產保存的重要方法。以保存客家文化為主要宗旨的客家博物館也逐步開展數位典藏，並有顯著的成果。不過客家博物館在數位典藏詮釋資料的發展與學術討論皆較少，亟需投入更多的研究，俾借助資通科技與數位環境，促進客家文化之發揚與傳播。客家文化資產數位網內容包含全國多間客家博物館之蒐藏以及許多存於民間的珍貴文化資產，內容相當豐富，但在各類型文化資產資料結構（欄位）的呈現上繁紛不一致，許多欄位的意義也難辨別，難以將豐碩的數位典藏內容完整展現於大眾眼前。為讓社會大眾得以深入鑽研客家文化深厚底蘊，本研究選擇以蒐藏多元的客

家文化資產數位網為案例，透過資料結構標準與客家數位典藏欄位之回顧，作為本研究分析的學理基礎資訊，接著以比較分析法進行欄位調整，再訪談客家學者、客發中心典藏人員與普查人員，檢視調整後欄位的合理性與適用性，最終整理出一套50個數位典藏詮釋資料欄位的客家文化資產數位網詮釋資料結構。研究結果顯示前述以「整合」為原則的客家文化資產數位網詮釋資料結構欄位，應能涵蓋表達客家文化資源重要資訊之需求。本研究最後依據研究結論提出客家博物館詮釋資料規劃的建議：(1)針對館內多種詮釋資料欄位可進行整合分析、(2)應為館內詮釋資料欄位編擬相關著錄規則、(3)確實區分欄位詮釋主體，避免著錄時的混淆、(4)適度開放民眾所需

的詮釋資料。依據上述建議，本研究另提出3點未來研究方向：(1)研究範圍拓展至客發中心所有的典藏作業、(2)納入資料內容標準與資料值標準進行探討(3)建置一套適用於全國客家博物館的詮釋資料標準。期望本研究成果可供客家博物館建置數位典藏時作參考之用。

The Chemical Transformations of C1 Compounds

為了解決Subcommittee的問題，作者 這樣論述：

Xiao-Feng Wu studied chemistry in Zhejiang Sci-Tech University (China), where he got his bachelor’s degree in science (2007). In the same year, he went to Rennes 1 University (France) and earned his master’s degree in 2009. Then he joined Matthias Beller’s group in Leibniz-Institute for Catalysis (G

ermany), where he completes his PhD defense in January 2012. Subsequently he started his independent research at LIKAT and ZSTU where he was promoted to professor in 2013. In March 2017, Xiao-Feng defended his Habilitation successfully from Rennes 1 University (France). Xiao-Feng has authored >300 p

ublications in international journals, meanwhile he is also the editor or author of >10 books. Buxing Han received his Ph.D. at the Institute of Chemistry, Chinese Academy of Sciences (CAS), in 1988, and did postdoctoral research from 1989 to 1991 at the University of Saskatchewan, Canada. He has b

een a professor at the Institute of Chemistry, CAS, since 1993. He is an academician of the Chinese Academy of Sciences; a fellow of the Academy of Sciences for the Developing World (TWAS); a fellow of the Royal Society of Chemistry; the chairman of the Green Chemistry Committee, Chinese Chemical So

ciety; the former chairman of the International Union of Pure and Applied Chemistry (IUPAC) Subcommittee on Green Chemistry; and a former titular member of Division III of IUPAC. Buxing Han has published >300 papers, >20 patents. Kuiling Ding received his B.S. in chemistry from Zhengzhou University

in 1985 before studying physical organic chemistry at Nanjing University, where he received a Ph.D. in 1990 with Professor Yangjie Wu. He became an assistant professor at Zhengzhou University in 1990 and a full professor at the same university in 1995. During 1993-1994, he was engaged in a postdoct

oral research with Professor Teruo Matsuura at Ryukoku University in Japan. In the period from 1997 to 1998, he was a UNESCO research fellow with Professor Koichi Mikami at Tokyo Institute of Technology in Japan. He joined Shanghai Institute of Organic Chemistry, CAS, in Dec of 1998 as a professor o

f chemistry and had been the director of the institute in the period of 2009-2019. He moved to Shanghai Jiaotong University as an executive vice president in 2018. His research interests include the development of new methodologies and novel catalysts for green & sustainable chemistry including asym

metric catalysis and CO2 transformation. He received National Natural Science Award of China in 2009, the 1st Yoshida Prize of International Organic Chemistry Foundation (IOCF) Japan in 2015, and Humboldt Research Award in 2016. He was elected a member of Chinese Academy of Sciences in 2013. Zhongm

in Liu received his PhD in Physical Chemistry from Dalian Institute of Chemical Physics (DICP) in 1990. He is the member of Chinese Academy of Engineering. He has been the Director of DICP and the Director of Qingdao Institute of Bioenergy and Bioprocess Technology, CAS, since 2017. Prof. Liu, toget

her with partners and his colleagues, has successfully accomplished the industrial demonstration test of methanol to olefin technology (DMTO) in 2006. Based on DMTO, the world’s first commercial coal to olefin plant was built in 2010, which was a milestone for C1 resource to chemicals. Up to now, 24

DMTO units have been licensed with the olefins production capacity of 13.86 million t/a. Prof. Liu and his team also developed an ethanol production process via carbonylation of DME and further hydrogenated, which leads to the world’s first 10 KTA coal to ethanol plant in 2017 in Shaanxi, China. He

has also developed many other new catalysts and catalytic process, such as propylene to isopropanol, and methanol to dimethyl ether. Many of them have been commercialized. He published more than 300 papers, filed 300 patents and got many awards such as The National Technological Invention Awards Fi

rst Prize on DMTO.

服用新型口服抗凝血藥物患者基因多型性與凝血功能相關性研究

為了解決Subcommittee的問題，作者陳瑋 這樣論述：

心房纖維顫動(Atrial fibrillation, AF)發生率及盛行率逐年增加且罹患中風風險較高，因此臨床上預防性服用新型口服抗凝血劑(Novel Oral Anticoagulants, NOACs)人數也隨之上升。儘管NOACs相較於傳統的維生素K拮抗劑(Vit K antagonist, VKAs)不需凝血功能監測追蹤，但抗凝血劑依舊有出血風險，本研究欲觀察影響NOACs代謝相關基因(ABCB1、ABCG2、CYP3A5、CES1)之單一核苷酸多型性(Single-nucleotide polymorphisms, SNP)與臨床常見凝血功能監測凝血酶原時間(Prothrombi

n time, PT)及部份凝血活酶時間(Activated partial thromboplastin Time, aPTT)之間是否有關聯性。自2021年3月至2022年3月期間於高雄醫學大學附設醫院及高雄市立大同醫院心臟內科共收集了95名服用NOACs患者(63男32女，平均年齡69.87±8.95)，使用醫院病歷調閱病人檢驗數值、問卷收集生活習慣，最後針對用藥時間收集最高血中藥物濃度(Cmax)與最低血中藥物濃度(Cmin)的凝血功能時間，萃取病人血液中DNA以即時聚合酶連鎖反應 (Real-Time Polymerase Chain Reaction, Real-Time PCR)

找出病人SNP位點，觀察其SNPs、檢驗數值、凝血功能(PT/aPTT)與生活習慣之間影響。研究結果發現基因CES1 rs8192935 (A/G)與肝功能丙胺酸轉胺(Glutamic Pyruvic Transaminase, GPT)間有顯著差異(p